Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 19
2003 15
2004 30
2005 26
2006 29
2007 27
2008 21
2009 33
2010 15
2011 25
2012 25
2013 22
2014 24
2015 14
2016 15
2017 20
2018 17
2019 19
2020 19
2021 13
2022 11
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

400 results

Results by year

Filters applied: . Clear all
Page 1
[Multiple myeloma with IgH::MYC and multiple extramedullary lesions].
Sasaki Y, Ichikawa S, Sakurai K, Nakamura H, Inokura K, Onodera K, Fukuhara N, Onishi Y, Yokoyama H, Harigae H. Sasaki Y, et al. Among authors: nakamura h. Rinsho Ketsueki. 2024;65(3):147-152. doi: 10.11406/rinketsu.65.147. Rinsho Ketsueki. 2024. PMID: 38569857 Japanese.
The pretreatment Controlling Nutritional Status score is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma.
Kaneda Y, Kanemura N, Nakamura N, Ikoma Y, Yamaguchi K, Takada E, Shibata Y, Lee S, Fujita K, Morishita T, Matsumoto T, Nakamura H, Kitagawa J, Kasahara S, Hara T, Tsurumi H, Shimizu M. Kaneda Y, et al. Among authors: nakamura h. Leuk Lymphoma. 2024 Mar;65(3):339-345. doi: 10.1080/10428194.2023.2295787. Epub 2023 Dec 20. Leuk Lymphoma. 2024. PMID: 38124378
A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non-Hodgkin lymphoma.
Ikoma Y, Nakamura N, Kitagawa J, Miwa T, Takada E, Matsumoto T, Shibata Y, Nakamura H, Kanemura N, Kasahara S, Hara T, Sawada M, Tsurumi H, Shimizu M. Ikoma Y, et al. Among authors: nakamura h. Hematol Oncol. 2024 Jan;42(1):e3236. doi: 10.1002/hon.3236. Epub 2023 Nov 6. Hematol Oncol. 2024. PMID: 37932900 Clinical Trial.
Comparison of the prognostic impact of IPI and PIT in peripheral T-cell lymphoma in real-world practice with a large elderly population.
Nakamura N, Kanemura N, Matsumoto T, Nakamura H, Ikoma Y, Shibata Y, Kitagawa J, Kasahara S, Yamada T, Sawada M, Kaneda Y, Fukuno K, Takada E, Goto H, Lee S, Fujita K, Morishita T, Hara T, Tsurumi H, Shimizu M. Nakamura N, et al. Among authors: nakamura h. Sci Rep. 2023 Nov 4;13(1):19060. doi: 10.1038/s41598-023-46501-5. Sci Rep. 2023. PMID: 37925551 Free PMC article.
Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes with Donor-Specific Anti-HLA Antibodies against HLA-DP.
Uchibori Y, Onodera K, Onishi Y, Komatsu H, Takenaka K, Narumi Y, Watanabe T, Nakamura H, Sakurai K, Hashimoto K, Inokura K, Ichikawa S, Fukuhara N, Yokoyama H, Harigae H. Uchibori Y, et al. Among authors: nakamura h. Tohoku J Exp Med. 2023 Oct 17;261(2):123-127. doi: 10.1620/tjem.2023.J063. Epub 2023 Aug 10. Tohoku J Exp Med. 2023. PMID: 37558420 Free article.
400 results